Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

BACKGROUND/AIMS: To provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD). METHODS: Setting: Multicentre. Design: Randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bressler, Neil M, Veith, Miroslav, Hamouz, Jan, Ernest, Jan, Zalewski, Dominik, Studnička, Jan, Vajas, Attila, Papp, András, Vogt, Gabor, Luu, James, Matuskova, Veronika, Yoon, Young Hee, Pregun, Tamás, Kim, Taehyung, Shin, Donghoon, Oh, Inkyung, Jeong, Hansol, Kim, Mercy Yeeun, Woo, Se Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985746/
https://www.ncbi.nlm.nih.gov/pubmed/34656987
http://dx.doi.org/10.1136/bjophthalmol-2021-319637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985746/
https://www.ncbi.nlm.nih.gov/pubmed/34656987
http://dx.doi.org/10.1136/bjophthalmol-2021-319637

Ejemplares similares